Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Two Inactivated Polio Vaccines Approved By Ministry

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor, and Welfare approved a quadruple inactivated polio vaccine July 27.

Japan's Ministry of Health, Labor, and Welfare approved a quadruple inactivated polio vaccine July 27. The vaccination is for the prevention of polio, pertussis, diphtheria, tetanus and is administered using the Tetrabik subcutaneous injection syringe made by the Research Foundation for Microbial Diseases of Osaka University and the Quattrovac subcutaneous injection syringe made by Kaketsuken. The single inactivated polio vaccine Imovax from Sanofi Pasteur was approved in April, but this is the first approval for a quadruple vaccine. Release dates are still unknown, but Tetrabik will be sold by Mitsubishi Tanabe Pharmaceuticals while Quattrovac will be sold by Astellas Pharmaceuticals. (Click Here For More – Japanese Language)

“Ministry: 2 Inactivated Polio Vaccines Approved” -mixonline.jp (7/31/2012)

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC081935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel